Bradley S. Quon
St. Paul's Hospital
Vancouver, BC, Canada
Vancouver, BC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 130 publications
Impact of Elexacaftor/Tezacaftor/Ivacaftor (ETI) on Airway and Aystemic Inflammation in Cystic Fibrosis: A Systematic Review.
Journal: Annals of the American Thoracic Society
Published: February 23, 2026
Real-world impact of elexacaftor/tezacaftor/ivacaftor on health-related quality of life in adults with cystic fibrosis: A 12-month multicenter cohort study.
Journal: Respiratory medicine
Published: October 31, 2025
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: results from an open-label extension study.
Journal: Annals of the American Thoracic Society
Published: October 03, 2025
Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: September 22, 2025
Hepatitis E virus seroprevalence is increased amongst pancreatic insufficient adults with cystic fibrosis - A single centre study.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: July 14, 2025
Characterizing individuals with elevated sweat chloride results in the absence of CFTR variants.
Journal: Orphanet journal of rare diseases
Published: July 06, 2025
Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study.
Journal: American journal of respiratory and critical care medicine
Published: June 13, 2025
Time to replace the oral glucose tolerance test for cystic fibrosis related diabetes first-step screening? Establishing glycemic tools relevant to cystic fibrosis.
Journal: Annals of medicine
Published: June 05, 2025
Biomarkers associated with clinical response to cystic fibrosis pulmonary exacerbation treatment and adjuvant prednisone therapy.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: May 31, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study.
Journal: American journal of respiratory and critical care medicine
Published: April 10, 2025
Early life inflammation in CF: can it be reversed by CFTR modulators?
Journal: Thorax
Published: April 02, 2025
Last Updated: 09/26/2026